Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 6, 2026

Stocks Roar Back as Beaten-Down Tech Sector Rebounds

View original at nasdaq.com
Stocks Roar Back as Beaten-Down Tech Sector Rebounds The S&P 500 Index ($SPX) (SPY) on Friday closed up +1.97%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +2.47%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +2.15%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings are expected to increase by +4.6%

    80% confidence

  • CICC recommends outperform rating on Caterpillar with price target of $800

    80% confidence

  • S&P earnings growth expected to climb by +8.4% in Q4, marking the tenth consecutive quarter of year-over-year growth

    80% confidence

  • Doximity forecasts full-year revenue of $642.5 million to $643.5 million

    80% confidence

  • Roblox forecasts full-year bookings of $8.28 billion to $8.55 billion

    80% confidence

  • Fed Vice Chair is cautiously optimistic about US economy outlook and strong productivity growth could help return inflation to Fed's 2% target

    80% confidence

  • Gen Digital forecasts full-year adjusted EPS of $2.54 to $2.56

    80% confidence

  • FDA will take swift action against companies mass-marketing illegal copycat drugs claiming they are similar to FDA-approved products

    80% confidence

  • It's paramount for the Fed to keep monetary policy in a restrictive posture so that we get inflation back to 2%

    80% confidence

  • Citigroup upgraded Estee Lauder to buy from neutral with price target of $120

    80% confidence

  • Bill Holdings raised full-year adjusted EPS forecast to $2.33 to $2.41 from previous forecast of $2.11 to $2.25

    80% confidence

  • Goldman Sachs upgraded Vistra to buy from neutral with price target of $205

    80% confidence

  • Centene forecasts full-year revenue of $186.5 billion to $190.5 billion

    80% confidence

  • Molina Healthcare forecasts full-year adjusted EPS of at least $5.00

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stocks Roar Back as Beaten-Down Tech Sector Rebounds — Source | Via News | ViaNews EU